These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 16370924)
1. Tirofiban for the treatment of ischaemic stroke. Bukow SC; Daffertshofer M; Hennerici MG Expert Opin Pharmacother; 2006 Jan; 7(1):73-9. PubMed ID: 16370924 [TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Leclerc JR Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256 [TBL] [Abstract][Full Text] [Related]
3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
4. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Mandava P; Thiagarajan P; Kent TA Drugs; 2008; 68(8):1019-28. PubMed ID: 18484795 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke. Lapchak PA; Araujo DM Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935 [TBL] [Abstract][Full Text] [Related]
6. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074 [TBL] [Abstract][Full Text] [Related]
7. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
8. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
13. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845 [TBL] [Abstract][Full Text] [Related]
15. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ; Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986 [TBL] [Abstract][Full Text] [Related]
16. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
18. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Moser M; Bertram U; Peter K; Bode C; Ruef J J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060 [TBL] [Abstract][Full Text] [Related]
19. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Alexander JH; Harrington RA Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986 [TBL] [Abstract][Full Text] [Related]
20. Current strategies with high-dose tirofiban. Mukherjee D; Roffi M Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]